Yazar "Karakaş, Zeynep" seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe COVID-19 infection in children with cancer and stem cell transplant recipients in Turkey: A nationwide study(Wiley, 2021) Kebudi, Rejin; Kurucu, Nilgün; Tuğcu, Deniz; Hacısalihoğlu, Şadan; Fışgın, Tunç; Ocak, Süheyla; Tokuç, Gülnur; Özdemir, Gül Nihal; Bozkurt, Ceyhun; İnce, Dilek; Aras, Seda; Ayçiçek, Ali; Aksoy, Başak Adaklı; Karadaş, Nihal; Öztürk, Gülyüz; Orhan, Mehmet Fatih; Ataseven, Eda; Akbayram, Sinan; Yılmaz, Ebru; Tüfekçi, Özlem; Vural, Sema; Akyay, Arzu; Ayhan, Aylin Canbolat; Kılıç, Suar; Uzel, Veysiye Hülya; Düzenli, Yeter; Kazanci, Elif Güler; Acıpayam, Can; Elli, Murat; Tanyeli, Atilla; Karakaş, Zeynep; Somer, Ayper; Kara, AteşAdults with cancer are reported to have a higher risk for coronavirus disease (COVID-19) infection and more severe disease and mortality than the general population.1,2 Although children seem to be at a lower risk for COVID-19 than adults,3–5 data specifically addressing children with cancer are limitedÖğe Dicle Üniversitesi Çocuk kliniğinde 1990-1993 yılları arasında izlenen akut lösemi olgularının değerlendirilmesi(İstanbul Üniversitesi Tıp Fakültesi-Bizim Lösemili Çocuklar Vakfı, 1993) Narlı, Nejat; Kılınç, Metin; Karakaş, Zeynep; Hoş, Aziz; Kırıcı, Galip; Devecioğlu, Celal; Gökten, İmadettin; Haspolat, Yusuf Kenan; Taş, M. Ali; Ay, ErhanDicle Üniversitesi Tıp Fakültesi Çocuk Sağlığı ve Hastalıkları Anabilim Dalında Ocak 1990-Mart 1993 arasında izlenen akut lösemi tanısı konan 76 hasta, yaş, cins, klinik, laboratuvar bulguları, tedavi sonuçları ve komplikasyonlar açısından retrospektif olarak değerlendirildi.Öğe Dicle Üniversitesi çocuk kliniğinde izlenen Burkitt lenfoma olguları(Ekin Yayıncılık, 1991) Karakaş, Zeynep; Haspolat, Yusuf Kenan; Demirel, NurtenDicle Üniversitesi Çocuk Kliniğinde 1989-1990 yıllarında izlenen 6 Burkitt Lenfoma olgusu incelendi. Hastaların en küçüğü 4, en büyüğü 7 yaşında olup ortalama yaş 6 idi. Primer tümör %16,7 hastada çenede, % 83,3 hastada batındaydı. Başvuru sırasında 5 hastada ( % 83,3) hastalık yaygın formdaydı. Tedaviye alınabilen 5 hastanın 3'üne (%60) NHL-LSA-L2, 2'sine (%40) Modifiye Ziegler tedavi protokolu uygulandı.Öğe Homozygous c.130-131 ins A (pW44X) mutation in the HAX1 gene as the most common cause of congenital neutropenia in Turkey: Report from the Turkish Severe Congenital Neutropenia Registry(Wiley, 2019) Karapınar, Deniz Yılmaz; Patıroglu, Türkan; Metin, Ayşe; Çalışkan, Ümran; Celkan, Tiraje; Yılmaz, Barış; Karakaş, Zeynep; Söker, Murat; 0000-0002-1637-4678; 0000-0002-6542-0570; 0000-0001-8463-2723Background Severe congenital neutropenia is a rare disease, and autosomal dominantly inherited ELANE mutation is the most frequently observed genetic defect in the registries from North America and Western Europe. However, in eastern countries where consanguineous marriages are common, autosomal recessive forms might be more frequent. Method Two hundred and sixteen patients with severe congenital neutropenia from 28 different pediatric centers in Turkey were registered. Results The most frequently observed mutation was HAX1 mutation (n = 78, 36.1%). A heterozygous ELANE mutation was detected in 29 patients (13.4%) in our cohort. Biallelic mutations of G6PC3 (n = 9, 4.3%), CSF3R (n = 6, 2.9%), and JAGN1 (n = 2, 1%) were also observed. Granulocyte colony-stimulating factor treatment was given to 174 patients (80.6%). Two patients died with infectious complications, and five patients developed myelodysplastic syndrome/acute myeloblastic leukemia. The mean (+/- mean standard error) follow-up period was 129.7 +/- 76.3 months, and overall survival was 96.8% (CI, 94.4-99.1%) at the age of 15 years. In Turkey, severe congenital neutropenia mostly resulted from the p W44X mutation in the HAX1 gene. Conclusion In Turkey, mutation analysis should be started with HAX1, and if this is negative, ELANE and G6PC3 should be checked. Because of the very high percentage of consanguineous marriage, rare mutations should be tested in patients with a negative mutation screen.Öğe Nefrotik sendromlu çocuklarda tiroid fonksiyonları(Yüce Reklam Yayıncılık, 2004) Avgen, Bahar; Kılınç, Metin; Karakaş, Zeynep; Narlı, Nejat; Kaya, Halil; Haspolat, Yusuf Kenan; Yıldız, MustafaDicle Üniversitesi Tıp Fakültesi Çocuk Sağlığı ve Hastalıkları Kliniği'nde minimal lezyonlu nefrotik sendrom tanısıyla izlenen en küçüğü iki, en büyüğü 11 yaşında olan 7'si erkek, 5'i kız 12 hastada ilk tanı konduğunda ve ortalama 5.8 ay kortizon tedavisi aldıktan sonra tiroid fonksiyonları ve tiroid otoantikorları çalışıldı.Öğe Outcomes of eltrombopag treatment and development of iron deficiency in children with immune thrombocytopenia in Turkey(Turkish Society of Hematology, 2020) Yozgat, Ayça Koca; Leblebisatan, Göksel; Akbayram, Sinan; Özel, Simge Çınar; Karakaş, Zeynep; Erduran, Erol; Söker, MuratObjective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5±4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of ≥50x109/L was 11.6±8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8±9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients. Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.
